Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)

Inclusion criteria: * Patients 18 years of age or older who have given their written consent to participate in the study. * Hospitalized and treated with oxygen for a maximum of 48 hours. * Verified Covid-19: Positive sample for Sars-Cov2 RNA or a positive Sars-Cov2 antigen test from the upper respiratory tract * Receives oxygen treatment. * Negative pregnancy test (women of childbearing potential) * Willing to exercise contraception categorized as "very effective" according to the Clinical Trial Facilitation Group during ongoing study treatment + 7 days (Appendix 2). (female research participant of childbearing potential) Exclusion criteria: * Pregnancy, breast-feeding or planned pregnancy. * Hypersensitivity to ciclesonide or to any of the excipients. * Concomitant medication with cortisone, ketoconazole, itraconazole, ritonavir or nelfinavir. * Treatment with\> 8 l oxygen / min or supply of \> 50% oxygen with nasal high-flow cannula * Ongoing palliative care or expected survival of less than 72 hours. * Expected admission to the intensive care unit within 48 hours. * Active or inactive pulmonary tuberculosis. * Severe Liver Failure (Child-Pugh C) * Diagnosed with pulmonary arterial hypertension (PAH) or fibrosis. * Mental inability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study. * Participates in or has recently participated in a clinical trial in the last 30 days. Previous participation in this study.